MONTREAL, July 4, 2018 /CNW Telbec/ - Pharmascience Inc. is proud to launch today in CanadaPrpms-TRANDOLAPRIL (angiotensin-converting enzyme inhibitor), indicated for the treatment of mild to moderate essential hypertension and the treatment following acute myocardial infarction.
"The launch of Prpms-TRANDOLAPRIL allows us to be the first generic bioequivalent to PrMAVIK® available on the Canadian market." said Jean-Guy Goulet, Chief Operating Officer at Pharmascience Inc.
In the case of mild to moderate essential hypertension, Prpms-TRANDOLAPRIL can be used alone or in association with thiazide diuretics. It can also be used for the treatment following acute myocardial infarction in clinically stable patients who have a left ventricular dysfunction, whether they do or do not have heart failure symptoms, to improve survival and reduce hospitalizations for heart failure.1
High blood pressure significantly increases the risk of stroke, ischemic heart disease, peripheral vascular disease and heart failure. About 7.5 million Canadians live with this condition.2
"The launch of this product demonstrates the great agility of our teams, who are dedicated to offering Canadian patients quality and lower cost treatments." added M. Goulet.
About Pharmascience Inc.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with over 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 51st among Canada's top 100 Research & Development (R&D) investors with over $49 million invested in 2016, Pharmascience Inc. is the 3rd largest manufacturer of over-the-counter generic drugs in the country.
Pharmascience Inc. is a leading manufacturer and marketer of prescription generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. The company commercializes nearly 300 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.
In 2018, the prestigious Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers. Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as a partner of choice to increase access to medicine. Pharmascience's total donations of essential medicine is close to $70 million.